Atricure Inc. Stock
Atricure Inc. Stock
The Atricure Inc. price is unchanged compared to yesterday.
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Atricure Inc..
As a result the target price of 43 € shows a very positive potential of 86.96% compared to the current price of 23.0 € for Atricure Inc..
Pros and Cons of Atricure Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atricure Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atricure Inc. | 0.000% | -2.542% | -1.709% | -62.903% | -32.353% | -62.903% | -61.983% |
| SI-BONE Inc | -1.530% | 9.167% | 18.018% | -20.606% | -22.485% | - | - |
| Lantheus Holdings Inc | -0.230% | 2.817% | 19.346% | 22.346% | 53.147% | 4.435% | - |
| Cryolife Inc. | 0.000% | -8.901% | -43.506% | -31.361% | -55.442% | 25.180% | -26.271% |
Comments
AtriCure (ATRC) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (ATRC) was upgraded by Freedom Capital to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (NASDAQ:ATRC) was given a new $55.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
News
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
This medical device innovator for cardiac surgery reported an insider sale amid a year of negative total returns.
Doraiswamy Vinayak, Chief Scientific Officer of AtriCure (NASDAQ:ATRC), reported the
